Cardiff Oncology Inc
CRDF
Get informed when a big investor buys or sells
+ FollowMarket Cap$105.59M
Close$
$0.00
99.7% downside
Current Fair Value
99.7% downsideOvervalued by 99.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $105.59 Million |
|---|---|
| Enterprise Value | $96.85 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.69 |
| Beta | 1.46 |
| Outstanding Shares | 68,397,000 |
Return
| Return on Equity | -151.00% |
|---|---|
| Return on Assets | -107.33% |
| Return on Invested Capital | -155.56% |
Valuation & Multiples
| P/E Ratio | -2.28 |
|---|---|
| PEG | 6.75 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 454.7 |
| Enterprise Value to EBIT | -2.35 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$62,778
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$67,222
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0916▼ 3.11% |
|---|---|
| Total Calls | 265,400▼ 46.91% |
| Total Puts | 24,300▼ 60.36% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 27.42%▼ 8.57% |
|---|---|
| Total Invested | $24.26M▼ 38.96% |
| Investors Holding | 110▼ 10.00% |
ESG Score
No data
About Cardiff Oncology Inc
CEO: Mark Erlander